No Data
No Data
Processa Pharmaceuticals Appoints Russell Skibsted as CFO
Processa Pharmaceuticals (PCSA) said Wednesday it appointed Russell L. Skibsted as chief financial officer, effective immediately.Skibsted succeeds James Stanker, who is retiring but will remain
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alimera Sciences, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - June 27, 2024) - Rigrodsky Law, P.A. is investigating Alimera Sciences, Inc. ("Alimera") (NASDAQ: ALIM) regarding possible breaches of fiduciary duties and othe
Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8
12:01 PM EDT, 06/25/2024 (MT Newswires) -- Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8 Price: 5.52, Change: -0.02, Percent Change: -
Express News | Alimera Sciences Inc : Alliance Global Partners Cuts to Neutral From Buy
Craig-Hallum Upgrades Alimera Sciences(ALIM.US) to Buy Rating, Raises Target Price to $8
Craig-Hallum analyst Chase Knickerbocker upgrades $Alimera Sciences(ALIM.US)$ to a buy rating, and adjusts the target price from $5.5 to $8.According to TipRanks data, the analyst has a success rate o
Maxim Group Downgrades Alimera Sciences(ALIM.US) to Hold Rating
Maxim Group analyst Naz Rahman downgrades $Alimera Sciences(ALIM.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 27.7% and a total average return of -15.8% over the
No Data
OneNightOnly : Could be. Let's see how market reacts later.
JC88OP OneNightOnly: By the look of it, the volume is too low, if it can hit 6 bucks its already good lol